查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1916922

全球腮腺炎活活病毒疫苗市場（按疫苗類型、年齡層、技術、給藥途徑、劑量類型、配方和分銷管道分類）—預測（2026-2032 年）

Mumps Virus Vaccine Live Market by Vaccine Type, Age Group, Technology, Route Of Administration, Dose Type, Formulation, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年腮腺炎活病毒活病毒疫苗市值為 7.9424 億美元，預計到 2026 年將成長至 8.5701 億美元，年複合成長率為 7.36%，到 ​​2032 年將達到 13.0576 億美元。

主要市場統計數據
基準年 2025 7.9424億美元
預計年份：2026年 8.5701億美元
預測年份：2032年 13.0576億美元
複合年成長率 (%) 7.36%

透過對當前腮腺炎活疫苗市場格局的分析，確定疫苗研發者、支付者和免疫規劃設計者的策略重點。

腮腺炎仍是一種可透過疫苗預防的病毒性疾病，但偶爾會在免疫力下降、疫苗接種覆蓋率不足或各年齡層接種率不均衡的地區復發。過去十年，免疫策略日趨成熟，更加重視結合疫苗和簡化接種管道，既減輕了醫療服務提供者的工作負擔，也降低了錯失保護機會的風險。同時，疫苗技術的進步拓展了疫苗開發平臺，使其不再局限於傳統的活病毒疫苗，這迫使疫苗生產商和公共衛生機構重新評估其長期策略，以實現持續免疫和專案適應性。

確定將重塑疫苗研發、供應鏈和免疫規劃策略的關鍵技術、監管和物流變革。

疫苗領域正沿著多條匯聚的路徑不斷發展演變，改變了相關人員對研發、生產和分發的優先順序。科學創新是關鍵驅動力，重組平台和基於DNA的候選疫苗與傳統活病毒疫苗方法並行發展。技術選擇的多樣化促使企業加大對平台柔軟性和模組化生產的投資。同時，監管機構正在簡化聯合疫苗的核准流程，這鼓勵生產商開發諸如麻疹-腮腺炎-德國麻疹(MMR) 和麻疹-腮腺炎-德國麻疹-水痘 (MMRV) 等產品，以簡化接種程序並提高接種的連續性。

分析2025年關稅調整對美國疫苗供應鏈、生產策略和採購韌性的系統性影響

2025年美國關稅政策的實施，為本已錯綜複雜的全球疫苗生態系統增添了新的複雜性。關稅調整直接影響進口原料、專用生物加工設備和成品疫苗的成本結構，促使生產者重新評估其籌資策略並考慮本地生產方案。因此，供應鏈決策越來越依賴在成本負擔、供應連續性和品管標準之間取得平衡。

整合產品類型、分銷管道、人口統計和技術偏好等多維細分，以指導有針對性的疫苗策略和營運設計。

差異化產品策略是基於疫苗類型、分銷管道、年齡層、技術、給藥途徑、劑型和配方等方面的精確細分。疫苗類型包括合併疫苗和單價疫苗，其中結合疫苗包括麻疹-腮腺炎-德國德國麻疹(MMR) 合併疫苗和麻疹-腮腺炎-德國麻疹(MMRV) 聯合疫苗，而單價疫苗則專注於對抗單一病原體。這種分類決定了臨床試驗設計和上市後監測的重點。分銷通路細分則充分考慮了診所、醫院藥局、線上藥局和零售藥局的重要性。在這些管道中，需要針對社區和專科診所、公立和私立醫院、直接面對消費者的線上藥房和第三方平台以及連鎖藥房和獨立藥房制定客製化的物流、計費流程和醫護人員培訓策略。

評估區域製造能力、監管複雜性和分銷基礎設施如何塑造美洲、歐洲、中東和非洲以及亞太地區的差異化策略。

區域趨勢對全球疫苗的製造地、監管方式和分銷模式有顯著影響。在美洲，成熟的製造群和健全的公共採購機制支持疫苗的快速擴張，但也使相關人員面臨貿易政策波動和供應集中風險。該地區的疫苗接種計劃通常依賴大規模醫院網路以及零售藥局在常規免疫接種服務中日益重要的作用，因此需要能夠同時滿足機構和消費者通路需求的靈活包裝和分銷解決方案。

競爭格局分析：成熟的製造商、生物技術創新者和專業服務供應商齊聚一堂，共同提供可擴展的疫苗解決方案和卓越的分銷服務。

腮腺炎活疫苗市場的競爭主要圍繞著現有疫苗生產商、生物技術創新者和契約製造組織（CMO）展開，它們共同決定著疫苗在生產、配方和分銷方面的能力和產能。現有生產商在規模、監管經驗以及與國家免疫規劃的現有合作關係方面擁有優勢，使其能夠支持大規模聯合疫苗部署並管理複雜的低溫運輸物流。新興企業和生物技術公司則透過重組技術和DNA平台進行創新，並經常與成熟公司和契約製造合作，以獲得填充包裝能力和全球分銷網路。

經營團隊可採取的策略重點，以增強生產柔軟性、最佳化產品設計以適應通路，並降低地緣政治和關稅風險。

產業領導者應採取務實且優先的行動方案，以增強專案韌性並提升商業性成果。首先，技術應投資多元化，涵蓋活病毒疫苗、重組疫苗和DNA疫苗平台，以對沖科學和監管風險，同時保留聯合疫苗研發的選擇空間。同時，他們應透過投資區域灌裝密封能力和模組化設施，提高生產柔軟性，以便快速應對需求波動和貿易政策變化。這些投資將縮短前置作業時間，並降低單一供應來源中斷的風險。

我們描述了一種嚴謹的混合方法研究途徑，該方法結合了相關人員訪談、文獻分析和迭代檢驗，以確保研究結果具有可操作性和檢驗。

為確保分析的有效性和相關性，本研究採用混合方法，結合了與關鍵相關人員的直接對話、二手文獻的綜合分析以及嚴謹的檢驗驗證。關鍵資訊透過與臨床開發負責人、生產負責人、分銷合作夥伴和免疫專案經理的結構化訪談獲得，從而深入了解營運限制和策略重點。二級資訊來源包括同儕審查的文獻、監管指導文件和已發表的技術報告，用於闡釋技術進步和監管趨勢。

總結決定腮腺炎活疫苗領域長期可近性、韌性和公共衛生影響的策略要務和營運權衡。

腮腺炎活疫苗市場呈現出技術多樣化、分銷管道不斷演變以及對貿易和採購趨勢日益敏感的特徵。成功的策略必須將平台柔軟性與務實的營運選擇相結合，以便根據目標分銷管道的能力和不同年齡層的需求調整配方、劑量類型和給藥途徑。製造商和專案設計者在製定生產和灌裝包裝策略時，還必須權衡集中化規模生產和在地化應對力之間的利弊。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 腮腺炎病毒活病毒疫苗市場（依疫苗類型分類）

  • 聯合疫苗
    • 麻疹、腮腺炎、德國麻疹疫苗
    • 麻疹、腮腺炎、德國麻疹三重疫苗
  • 單抗原疫苗

9. 按年齡層別分類的腮腺炎病毒活病毒疫苗市場

  • 青春期
  • 成人
  • 兒童

10. 腮腺炎病毒活病毒疫苗市場（依技術分類）

  • DNA疫苗
  • 減毒活病毒疫苗
  • 重組疫苗

第11章 依給藥途徑分類的活病毒疫苗市場

  • 肌肉內注射
  • 皮下注射

12. 腮腺炎病毒活病毒疫苗市場（依劑量類型分類）

  • 多劑量
  • 單一劑量

13. 腮腺炎病毒活病毒疫苗市場（依製劑類型分類）

  • 液體
  • 凍乾粉

第14章 腮腺炎病毒活病毒疫苗市場（依通路分類）

  • 診所
    • 社區診所
    • 專科診所
  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 直接面對消費者的藥房
    • 第三方市場
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

15. 各地區腮腺炎病毒活病毒疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 腮腺炎病毒活病毒疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國腮腺炎病毒活病毒疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國活病毒疫苗市場

17. 中國的活病毒疫苗市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca
  • Bavarian Nordic
  • Bharat BIoTech International Limited
  • Biological E. Limited
  • CSL Limited
  • GSK plc
  • Hualan Biological Engineering Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Sinovac BIoTech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
Product Code: MRR-AE420CB153F8

The Mumps Virus Vaccine Live Market was valued at USD 794.24 million in 2025 and is projected to grow to USD 857.01 million in 2026, with a CAGR of 7.36%, reaching USD 1,305.76 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 794.24 million
Estimated Year [2026] USD 857.01 million
Forecast Year [2032] USD 1,305.76 million
CAGR (%) 7.36%

Contextualizing the modern live mumps vaccine environment to illuminate strategic priorities for developers, payers, and immunization program architects

Mumps remains a vaccine-preventable viral disease with episodic resurgences in communities that experience waning immunity, gaps in vaccine uptake, or heterogeneous coverage across age cohorts. Over the last decade, immunization strategies have matured to emphasize combination vaccines and streamlined delivery pathways that reduce missed opportunities for protection while addressing operational burdens on providers. At the same time, advances in vaccine technology have expanded the development pipeline beyond classical live attenuated approaches, prompting manufacturers and public health agencies to reassess long-term strategies for durable immunity and programmatic fit.

This introduction frames the contemporary live mumps vaccine landscape and positions the subsequent analysis around supply chain resilience, regulatory harmonization, and product differentiation. It highlights the interplay between technological innovation, distribution evolution, and demographic targeting across adolescent, pediatric, and adult populations. Importantly, the narrative acknowledges that program success depends on aligning formulation choices and dosing regimens with real-world constraints such as cold chain capacity and clinic workflows.

The following sections synthesize recent shifts in regulatory posture, tariff-driven trade dynamics, and segmentation insights that matter for clinical development and commercialization strategies. This groundwork is designed to inform executives, policy advisors, and commercial teams who must translate technical options into viable vaccination programs that achieve sustained population protection.

Identifying the major technological, regulatory, and distribution shifts that are reshaping vaccine development, supply chains, and immunization program strategies

The vaccine landscape is evolving along several convergent vectors that are altering how stakeholders prioritize development, manufacturing, and distribution. Scientific innovation is a primary driver, with recombinant platforms and DNA-based candidates advancing in parallel to traditional live attenuated approaches; this diffusion of technology choices is encouraging investment in platform flexibility and modular manufacturing. At the same time, regulatory authorities are refining pathways for combination products, which in turn incentivizes manufacturers to pursue MMR and MMRV formats that simplify immunization schedules and improve coverage continuity.

Concurrently, distribution paradigms are shifting away from single-channel models toward hybrid networks that integrate clinics, hospitals, retail pharmacies, and digital dispensing channels. This transformation is accelerating due to patient preferences for convenience and the growing role of pharmacies in routine immunizations. Supply chain modernization is another transformative shift: manufacturers are prioritizing cold chain optimization, lyophilized formulations, and single-dose presentations to reduce wastage and improve field usability, particularly in settings with constrained refrigeration.

Finally, demographic trends and vaccination policy debates are reshaping prioritization of age cohorts, with renewed attention on adolescent and adult booster strategies in addition to pediatric immunization. Taken together, these shifts create both opportunities and operational complexities; successful organizations are those that anticipate multi-stakeholder needs and adapt product strategy, commercial channels, and manufacturing footprints accordingly.

Analyzing the systemic effects of 2025 tariff adjustments on vaccine supply chains, manufacturing strategy, and procurement resilience in the United States

The implementation of tariff measures in 2025 by the United States introduced an added layer of complexity to an already intricate global vaccine ecosystem. Tariff adjustments have direct implications for the cost structure of imported raw materials, specialized bioprocess equipment, and finished vaccine consignments, prompting manufacturers to reassess sourcing strategies and consider localized production alternatives. As a result, supply chain decision-making is increasingly driven by the need to balance cost exposure with continuity of supply and quality control standards.

In response to tariff pressures, many stakeholders are accelerating nearshoring initiatives, expanding local fill-finish capacity, and renegotiating supplier agreements to secure preferential terms. This reorientation can improve lead-time resilience, but it also raises capital intensity and regulatory coordination burdens as manufacturers scale or repurpose facilities to meet domestic demand. Moreover, distributors and healthcare providers are adjusting procurement practices to mitigate price volatility; longer-term contracts and strategic stockpiles are being used alongside inventory management techniques to smooth supply disruptions.

Regulatory authorities and procurement agencies are becoming more active in facilitating cross-border collaboration to preserve access to critical immunization inputs. In practice, this has manifested as expedited reviews for facility changes, technical guidance on material substitutions, and targeted incentives to support manufacturing upgrades. Collectively, these measures aim to sustain vaccine availability while managing the financial consequences of trade policy shifts.

Integrating multidimensional segmentation across product type, channels, demographics, and technological choices to guide targeted vaccine strategies and operational design

Differentiated product strategies are informed by precise segmentation across vaccine type, distribution channel, age group, technology, route of administration, dose type, and formulation. Vaccine type distinctions include combination vaccines versus monovalent vaccines, with combination formats encompassing MMR and MMRV options and monovalent approaches focused on single pathogen presentations; this classification shapes clinical trial design and post-marketing surveillance priorities. Distribution channel segmentation recognizes the importance of clinics, hospital pharmacies, online pharmacies, and retail pharmacies; within those channels, community and specialty clinics, private and public hospitals, direct-to-consumer online pharmacies and third-party marketplaces, and chain versus independent retail pharmacies each require tailored logistics, billing processes, and provider education strategies.

Age group segmentation influences both immunogenicity objectives and communications strategy, with pediatric, adolescent, and adult cohorts exhibiting different dosing needs, booster considerations, and uptake barriers. Technological segmentation distinguishes DNA vaccines, live attenuated vaccines, and recombinant vaccine platforms, which carry distinct manufacturing footprints, cold chain requirements, and regulatory pathways. Considerations around route of administration-intramuscular versus subcutaneous-affect clinic workflow and training, while dose type choices between multi-dose and single-dose vials drive inventory management, wastage calculations, and cold storage demands. Finally, formulation segmentation between liquid solution and lyophilized powder has practical implications for stability in varied climates, reconstitution workflows, and shelf-life planning.

Integrating these segmentation dimensions yields granular insight into where product innovations and operational enhancements will yield the greatest return. For example, pairing a lyophilized formulation and single-dose presentation with pharmacy-based distribution may broaden access in outpatient settings, while recombinant platforms targeted at adolescent boosters could streamline regulatory acceptability and support longer-term immunity objectives.

Evaluating how regional manufacturing capacities, regulatory complexity, and distribution infrastructures shape differentiated strategies across the Americas, Europe Middle East Africa, and Asia Pacific

Regional dynamics exert strong influence on manufacturing placement, regulatory approaches, and distribution models across the global vaccine landscape. In the Americas, established manufacturing clusters and robust public procurement mechanisms support rapid scale-up but also expose stakeholders to trade policy volatility and concentrated supply risk. This region's vaccination programs often leverage large hospital networks and an expanding role for retail pharmacies in delivering routine immunizations, which in turn demands flexible packaging and distribution solutions that accommodate both institutional and consumer-facing channels.

Europe, Middle East & Africa reflects a heterogeneous mix of regulatory frameworks, infrastructure maturity, and financing models. High-income markets in Europe emphasize stringent regulatory harmonization and tend to adopt combination vaccines rapidly, whereas parts of the Middle East and Africa prioritize cold chain resilience, lyophilized formulations, and targeted deployment strategies to reach underserved populations. Cross-border collaboration and regional procurement mechanisms are increasingly important in this geographic cluster to address capacity gaps and to coordinate responses to disease outbreaks.

Asia-Pacific represents a complex mosaic of advanced biomanufacturing hubs alongside emerging production centers. Governments are investing in local production capacity and regulatory modernization to reduce import dependency and to support domestic public health priorities. Distribution pathways in this region need to accommodate vast geographic diversity and variable cold chain infrastructure, necessitating product formats and logistical partnerships that are adaptable to urban and remote settings alike. Taken together, regional considerations dictate differentiated commercialization plans, manufacturing investments, and public-private engagement strategies.

Profiling the competitive ecosystem where incumbent manufacturers, biotech innovators, and specialized service providers converge to deliver scalable vaccine solutions and distribution excellence

Competitive dynamics in the live mumps vaccine domain center on a mix of incumbent vaccine manufacturers, biotech innovators, and contract manufacturing organizations that collectively define capability and capacity for production, formulation, and distribution. Established manufacturers retain advantages in scale, regulatory experience, and incumbent relationships with national immunization programs, enabling them to support large-scale combination vaccine rollouts and to manage complex cold chain logistics. Emerging players and biotech firms are injecting innovation through recombinant and DNA platforms, often partnering with larger firms or contract manufacturers to access fill-finish capacity and global distribution networks.

Strategic alliances and licensing agreements are common as organizations seek to combine scientific novelty with commercial reach. Contract manufacturing organizations play a critical role by offering flexible capacity for lyophilized powder production and by providing regional fill-finish services that help firms mitigate tariff and supply chain risks. In parallel, service providers specializing in cold chain logistics and digital distribution are becoming more prominent, offering capabilities that expand access through retail and online pharmacy channels.

Across the competitive landscape, differentiation is increasingly based on end-to-end capabilities: the ability to move from platform R&D through scalable manufacturing to channel-ready product formats. Companies that pair technological flexibility with robust regulatory strategy and channel-specific commercialization plans are best positioned to capture opportunities arising from shifting demand patterns and evolving policy priorities.

Actionable strategic priorities for executives to strengthen manufacturing flexibility, optimize product design for distribution, and mitigate geopolitical and tariff risks

Industry leaders should pursue a set of pragmatic, prioritized actions to strengthen program resilience and commercial outcomes. First, diversify technology investments across live attenuated, recombinant, and DNA platforms to hedge scientific and regulatory risk while maintaining options for combination vaccine development. Simultaneously, expand manufacturing flexibility by investing in regional fill-finish capacity and modular facilities that can be repurposed quickly in response to demand shifts or trade policy changes. These investments will reduce lead times and limit exposure to single-source disruptions.

Second, align product design with distribution realities by selecting formulations and dose presentations that optimize cold chain utilization and reduce wastage. Prioritize lyophilized powder or single-dose formats for regions with limited refrigeration and favor combination vaccine formats where programmatic simplification can materially improve uptake. Third, broaden go-to-market strategies to include clinic networks, hospital pharmacies, retail pharmacy chains, and online dispensing channels, and create tailored engagement models for community and specialty clinics as well as public and private hospitals.

Fourth, strengthen stakeholder engagement through proactive regulatory dialogue, partnerships with local distributors, and health systems to accelerate approvals and reimbursement. Finally, implement scenario-based procurement planning to mitigate tariff impacts, including nearshoring options, diversified supplier agreements, and strategic stockpiling. These actions, taken together, will enhance resilience while positioning organizations to capitalize on emerging vaccination opportunities.

Explaining the rigorous mixed-methods research approach that combines stakeholder interviews, literature analysis, and iterative triangulation to ensure actionable and validated findings

This analysis draws upon a mixed-methods research approach that combines primary stakeholder engagement, secondary literature synthesis, and rigorous triangulation to ensure validity and relevance. Primary inputs were secured through structured interviews with clinical developers, manufacturing leads, distribution partners, and immunization program managers, enabling nuanced understanding of operational constraints and strategic priorities. Secondary sources included peer-reviewed literature, regulatory guidance documents, and publicly available technical reports to contextualize technological advances and regulatory trends.

Data synthesis employed cross-validation techniques to reconcile divergent perspectives and to surface consensus findings. The segmentation framework was applied iteratively to map product and channel attributes to demographic and regional considerations, while sensitivity checks were used to test the robustness of operational recommendations under varying supply chain scenarios. Quality assurance steps included expert review cycles and targeted follow-up interviews to clarify ambiguities and corroborate key assertions.

Limitations of the methodology are acknowledged: proprietary commercial data and confidential procurement terms were not directly accessible, and real-time tariff or policy shifts may alter near-term operational dynamics. Nevertheless, the approach is purposefully designed to deliver actionable insights by integrating practitioner perspectives with documentary evidence and expert validation.

Summarizing the strategic imperatives and operational trade-offs that will determine long-term access, resilience, and public health impact in the live mumps vaccine domain

The live mumps vaccine landscape is characterized by technological diversification, evolving distribution channels, and heightened sensitivity to trade and procurement dynamics. Successful strategies will integrate platform flexibility with pragmatic operational choices-matching formulation, dose type, and route of administration to the capabilities of targeted channels and the needs of distinct age cohorts. Manufacturers and program designers must also weigh the trade-offs between centralized scale and regional responsiveness when determining production and fill-finish strategies.

Regulatory engagement, partnership formation, and investment in cold chain and logistical capabilities are central to sustaining access and ensuring program effectiveness. In the face of tariff-driven uncertainty and shifting regional priorities, organizations that proactively diversify supply sources and invest in near-term resilience measures will be better positioned to maintain continuity of supply and to respond to outbreak-driven demand. Ultimately, the most effective responses will blend scientific rigor with operational pragmatism, enabling stakeholders to translate technical innovation into durable public health impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mumps Virus Vaccine Live Market, by Vaccine Type

  • 8.1. Combination Vaccine
    • 8.1.1. Mmr Vaccine
    • 8.1.2. MmrV Vaccine
  • 8.2. Monovalent Vaccine

9. Mumps Virus Vaccine Live Market, by Age Group

  • 9.1. Adolescent
  • 9.2. Adult
  • 9.3. Pediatric

10. Mumps Virus Vaccine Live Market, by Technology

  • 10.1. Dna Vaccine
  • 10.2. Live Attenuated Vaccine
  • 10.3. Recombinant Vaccine

11. Mumps Virus Vaccine Live Market, by Route Of Administration

  • 11.1. Intramuscular
  • 11.2. Subcutaneous

12. Mumps Virus Vaccine Live Market, by Dose Type

  • 12.1. Multi Dose
  • 12.2. Single Dose

13. Mumps Virus Vaccine Live Market, by Formulation

  • 13.1. Liquid Solution
  • 13.2. Lyophilized Powder

14. Mumps Virus Vaccine Live Market, by Distribution Channel

  • 14.1. Clinic
    • 14.1.1. Community Clinic
    • 14.1.2. Specialty Clinic
  • 14.2. Hospital Pharmacy
    • 14.2.1. Private Hospital
    • 14.2.2. Public Hospital
  • 14.3. Online Pharmacy
    • 14.3.1. Direct To Consumer Pharmacy
    • 14.3.2. Third Party Marketplace
  • 14.4. Retail Pharmacy
    • 14.4.1. Chain Pharmacy
    • 14.4.2. Independent Pharmacy

15. Mumps Virus Vaccine Live Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Mumps Virus Vaccine Live Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Mumps Virus Vaccine Live Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Mumps Virus Vaccine Live Market

19. China Mumps Virus Vaccine Live Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AstraZeneca
  • 20.6. Bavarian Nordic
  • 20.7. Bharat Biotech International Limited
  • 20.8. Biological E. Limited
  • 20.9. CSL Limited
  • 20.10. GSK plc
  • 20.11. Hualan Biological Engineering Inc.
  • 20.12. Johnson & Johnson
  • 20.13. Merck & Co., Inc.
  • 20.14. Pfizer Inc.
  • 20.15. Sanofi
  • 20.16. Serum Institute of India Pvt. Ltd.
  • 20.17. Sinovac Biotech Ltd.
  • 20.18. Takeda Pharmaceutical Company Limited
  • 20.19. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMR VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMR VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMR VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMRV VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMRV VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MMRV VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MONOVALENT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MONOVALENT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DNA VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DNA VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DNA VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMMUNITY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMMUNITY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMMUNITY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DIRECT TO CONSUMER PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DIRECT TO CONSUMER PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DIRECT TO CONSUMER PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY THIRD PARTY MARKETPLACE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY THIRD PARTY MARKETPLACE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY THIRD PARTY MARKETPLACE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 227. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 264. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 266. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 267. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 268. G7 MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 277. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 279. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 281. NATO MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY COMBINATION VACCINE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DOSE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY ONLINE PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA MUMPS VIRUS VACCINE LIVE MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)